Shen X Q, Bubulya A, Zhou X F, Khazak V, Golemis E A, Shemshedini L
University of Toledo, Department of Biology, Ohio 43606, USA.
Endocrine. 1999 Jun;10(3):281-9. doi: 10.1007/BF02738627.
Upon binding retinoic acid (RA), the retinoic acid receptors (RARs) are able to positively and negatively regulate transcription. It has been shown that the DNA-binding domain and carboxy terminus of RARs are necessary for the ligand-dependent ability of the receptor to repress AP-1 transcriptional activity. A fusion of these two regions, shown to constitutively inhibit AP-1 activity, was used in a yeast two-hybrid screen to identify a novel hRARalpha-interacting protein. This protein, hsRPB7, a subunit of RNA polymerase II, interacts with hRARalpha in the absence of RA and addition of RA disrupts the interaction. Truncation analysis indicates that hsRPB7 specifically interacts with the hRARalpha DNA-binding domain. This interaction appears to compromise transcription, since overexpressed hRARalpha, in the absence of RA, is able to repress the activity of several RNA polymerase II-dependent activators, including AP-1 and the glucocorticoid receptor. This repression is relieved by transfected hsRPB7, strongly suggesting that ligand-free hRARalpha can block AP-1 activity by sequestering hsRPB7. The repression is dependent on the integrity of the hRARalpha DBD, since a mutation within the DBD blocks both the hRARalpha-hsRPB7 interaction and ligand-free hRARalpha repression of AP-1. These results provide evidence that non-liganded hRARalpha can regulate transcription by directly interacting with RNA polymerase II, and thus suggest a novel pathway by which hRARalpha can cross-talk with AP-1 and perhaps other families of transcriptional activators.
视黄酸(RA)结合后,视黄酸受体(RARs)能够正向和负向调节转录。研究表明,RARs的DNA结合结构域和羧基末端对于受体依赖配体抑制AP-1转录活性的能力是必需的。这两个区域的融合体,已显示其可组成性抑制AP-1活性,被用于酵母双杂交筛选以鉴定一种新型的与人RARα相互作用的蛋白。这种蛋白,hsRPB7,是RNA聚合酶II的一个亚基,在没有RA的情况下与hRARα相互作用,而添加RA会破坏这种相互作用。截短分析表明,hsRPB7特异性地与hRARα的DNA结合结构域相互作用。这种相互作用似乎会损害转录,因为在没有RA的情况下过表达的hRARα能够抑制几种RNA聚合酶II依赖的激活因子的活性,包括AP-1和糖皮质激素受体。转染hsRPB7可缓解这种抑制,强烈表明无配体的hRARα可通过隔离hsRPB7来阻断AP-1活性。这种抑制依赖于hRARα DBD的完整性,因为DBD内的一个突变会阻断hRARα-hsRPB7相互作用以及无配体的hRARα对AP-1的抑制。这些结果提供了证据,表明未结合配体的hRARα可通过与RNA聚合酶II直接相互作用来调节转录,从而提示了一种hRARα可与AP-1以及可能与其他转录激活因子家族进行相互作用的新途径。